Metastatix, Inc. Granted Investigational New Drug (IND) Application for MSX-122
11/6/2007 12:31:38 PM
ATLANTA--(BUSINESS WIRE)--Metastatix, Inc., an emerging pharmaceutical company focused on the development of small molecule therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for MSX-122, a potent CXCR4 inhibitor that the company is developing for the treatment of a number of critical indications, including various cancers and inflammatory diseases. The IND acceptance will permit Metastatix to commence Phase I clinical studies in the U.S. to determine the safety and tolerability of MSX-122 for the treatment of solid tumors.
comments powered by